HomeMYCO • CNSX
add
Mydecine Innovations Group Inc
Previous close
$0.0050
Year range
$0.0050 - $0.025
Market cap
308.77K CAD
Avg Volume
14.43K
P/E ratio
-
Dividend yield
-
Primary exchange
CNSX
Market news
Financials
Income Statement
Revenue
Net income
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.63M | 85.17% |
Net income | -1.99M | -68.31% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.63M | -85.14% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 60.17K | 247.04% |
Total assets | 178.31K | -96.00% |
Total liabilities | 17.62M | 60.62% |
Total equity | -17.45M | — |
Shares outstanding | 61.76M | — |
Price to book | -0.02 | — |
Return on assets | -2,426.97% | — |
Return on capital | 40.42% | — |
Cash Flow
Net change in cash
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -1.99M | -68.31% |
Cash from operations | 46.57K | 293.10% |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | 46.57K | 301.45% |
Free cash flow | 388.85K | 111.06% |
About
Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.
In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021.
Mydecine's drug candidates include the psychedelics psilocybin, MYCO-004, and MYCO-005 and the novel MDMA-like entactogens MYCO-002, MYCO-006, and MYCO-007.
Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA and 6-BZT-MDMA as short-acting MDMA analogues. Wikipedia
Founded
2020
Headquarters
Website
Employees
3
